Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 27.

Journal Article

Ackermann, S., Cartolano, M., Hero, B., Roderwieser, A., Bartenhagen, C., Rosswog, C., Hertwig, F., Simon, T., Eggert, A., Speleman, F., Buettner, R., O'Sullivan, R., Thomas, R., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J., Peifer, M. and Fischer, M. (2018). A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S87 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Ackermann, S., Cartolano, M., Hero, B., Roderwieser, A., Bartenhagen, C., Rosswog, C., Hertwig, F., Simon, T., Eggert, A., Speleman, F., Buettner, R., O'sullivan, R., Thomas, R., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J., Peifer, M. and Fischer, M. (2018). A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S234 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Berthold, F., Faldum, A., Ernst, A., Boos, J., Dilloo, D., Eggert, A., Fischer, M., Fruehwald, M., Henze, G., Klingebiel, T., Kratz, C., Kremens, B., Krug, B., Leuschner, I, Schmidt, M., Schmidt, R., Schumacher-Kuckelkorn, R., von Schweinitz, D., Schilling, F. H., Theissen, J., Volland, R., Hero, B. and Simon, T. (2020). Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Ann. Oncol., 31 (3). S. 422 - 430. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Berthold, F., Volland, R., Proleskovskaya, I., Mazanek, P., Belogurova, M., Hoemberg, M., Simon, T., Hero, B. and Sterba, J. (2015). METRONOMIC THERAPY AS LOW TOXIC AND EFFECTIVE TREATMENT FOR RECURRENCES OF HIGH RISK NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S178 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Cernaianu, G., Simon, T., Berthold, F., Fischer, J. and Duebbers, M. (2016). Resectability and Local Relapse Pattern of Abdominal High-Risk Neuroblastoma. Pediatr. Blood Cancer, 63. S. S43 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Deubzer, H., Fabian, J., Opitz, D., Althoff, K., Lodrini, M., Astrahantseff, K., Hero, B., Volland, R., Beckers, A., De Preter, K., Patil, N., Abba, M., Wuenchel, J., Thole, T., Hu, J., Schweitzer, L., Mechtersheimer, G., Carter, D., Cheung, B., Popanda, O., von Deimling, A., Henrich, K. O., Westermann, F., Schwab, M., Koster, J., Versteeg, R., Marshall, G., Speleman, F., Zoeller, M., Allgayer, H., Fischer, M., Berthold, F., Kulozik, A., Witt, O., Schulte, J. and Eggert, A. (2015). MYCN TRANSCRIPTIONALLY REPRESSES CD9 TO TRIGGER AN INVASION-METASTASIS CASCADE IN NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S150 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

El Majdoub, F., Simon, T., Hoevels, M., Berthold, F., Sturm, V. and Maarouf, M. (2011). Interstitial Brachytherapy using Stereotactic Implanted (125)Iodine Seeds for Recurrent Medulloblastoma. Clin. Oncol., 23 (8). S. 532 - 538. LONDON: ELSEVIER SCIENCE LONDON. ISSN 0936-6555

Fischer, M., Oberthuer, A., Juraeva, D., Schmidt, R., Faldum, A., Berthold, F., Westermann, F., Brors, B., Simon, T. and Hero, B. (2014). REVISED RISK ESTIMATION AND TREATMENT STRATIFICATION OF LOW- AND INTERMEDIATE-RISK NEUROBLASTOMA PATIENTS BY INTEGRATING CLINICAL AND MOLECULAR PROGNOSTIC MARKERS. Pediatr. Blood Cancer, 61. S. S119 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Hero, B., Simon, T., Lode, H., Eggert, A. and Berthold, F. (2017). Feasibility and Toxicity of Busulfan and Melphalan Conditioning Regimen in the Context of the German Induction Chemotherapy. Pediatr. Blood Cancer, 64. S. S34 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Hero, B., Simon, T., Volland, R., Eggert, A., Fischer, M. and Berthold, F. (2015). BENIGN COURSE OF DISEASE IN LOCALIZED NEUROBLASTOMA SHOWING RELAPSE OR PROGRESSION. Pediatr. Blood Cancer, 62. S. S178 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Hilker, R., Mielke, Rüdiger, Berthold, F., Schröder, R. and Heiss, W.-D. (1998). Mischtumoren der Pinealisregion. Diagnostik und Therapie bei Vorliegen sezernierender Keimzelltumoranteile. Der Nervenarzt, 69 (6). pp. 519-524. Springer. ISSN 0028-2804

Ikram, F., Ackermann, S., Roels, E., Volland, R., Hero, B., Hertwig, F., Kocak, H., Dreidax, D., Henrich, K. O., Berthold, F., Nuernberg, P., Westermann, F. and Fischer, M. (2014). Transcription factor activating protein 2 beta (TFAP2B) mediates neuronal differentiation in neuroblastoma. Eur. J. Cancer, 50. S. 130 - 132. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Kraal, K. C. J. M., Bleeker, G. M., van Eck-Smit, B. L. F., van Eijkelenburg, N. K. A., Berthold, F., van Noesel, M. M., Caron, H. N. and Tytgat, G. A. M. (2017). Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients. Eur. J. Cancer, 76. S. 188 - 197. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

London, W., Moroz, V., Hero, B., Park, J. R., Valteau-Couanet, D., Nakagawara, A., Berthold, F., Matthay, K. K., Schleiermacher, G. and Machin, D. (2014). A NEUROBLASTOMA RISK CLASSIFICATION MODEL FOR DEVELOPING COUNTRIES: A STUDY FROM THE INTERNATIONAL NEUROBLASTOMA (NB) RISK GROUP (INRG) DATABASE. Pediatr. Blood Cancer, 61. S. S119 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Peinemann, F., van Dalen, E. C. and Berthold, F. (2016). Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review. Klinische Padiatr., 228 (3). S. 130 - 135. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-3824

Peinemann, F., van Dalen, E. C. and Berthold, F. (2016). Retinoic Acid for High-risk Neuroblastoma Patients after Autologous Stem Cell Transplantation Cochrane Review. Klinische Padiatr., 228 (3). S. 124 - 130. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-3824

Platschek, A. M., Kehe, L., Berthold, F., Baumann, F. T. and Strueder, H. K. (2014). A FEASIBLE COMPUTER-BASED EXERCISE PROGRAM FOR DAILY CLINICAL PRACTICE IN PAEDIATRIC ONCOLOGY INCREASES MOTIVATIONAL BENEFITS. Pediatr. Blood Cancer, 61. S. S398 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Rossig, C., Juergens, H., Schrappe, M., Moericke, A., Henze, G., von Stackelberg, A., Reinhardt, D., Burkhardt, B., Woessmann, W., Zimmermann, M., Gadner, H., Mann, G., Schellong, G., Mauz-Koerholz, C., Dirksen, U., Bielack, S., Berthold, F., Graf, N., Rutkowski, S., Calaminus, G., Kaatsch, P. and Creutzig, U. (2013). Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria. Pediatr. Blood Cancer, 60 (10). S. 1574 - 1582. HOBOKEN: WILEY. ISSN 1545-5017

Rosswog, C., Fassunke, J., Schoemig-Markiefka, B., Merkelbach-Bruse, S., Ackermann, S., Ortmann, M., Schulte, J., Westermann, F., Berthold, F., Simon, T., Hero, B. and Fischer, M. (2020). ALK Mutations in Primary and Relapsed Neuroblastoma in a GPOH Cohort. Pediatr. Blood Cancer, 67. S. S57 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Rosswog, C., Schmidt, R., Oberthuer, A., Juraeva, D., Brors, B., Westermann, F., Berthold, F., Simon, T., Hero, B., Faldum, A. and Fischer, M. (2015). DEVELOPMENT OF A SCORING SYSTEM BASED ON A PROGNOSTIC INDEX FOR RISK ASSESSMENT OF PATIENTS WITH NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S178 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Schmidt, M. C., Hero, B., Decarolis, B., Eggert, A., Berthold, F., Drzezga, A. and Simon, T. (2017). I-131-mIBG therapy in high-risk neuroblastoma patients at end of induction chemotherapy. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S772 - 1. NEW YORK: SPRINGER. ISSN 1619-7089

Schmidt, M. C., Hero, B., Decarolis, B., Eggert, A., Berthold, F., Drzezga, A. and Simon, T. (2016). I-131-meta-iodobenzylguanidine therapy improves survival in high-risk neuroblastoma patients with I-123-mIBG positive residual metastatic disease. Eur. J. Nucl. Med. Mol. Imaging, 43. S. S31 - 1. NEW YORK: SPRINGER. ISSN 1619-7089

Simon, T., Schmidt, M., Decarolis, B., Eggert, A., Berthold, F. and Hero, B. (2017). I-131-Meta-Iodobenzylguanidine (MIBG) Therapy Improves Survival in High-Risk Neuroblastoma Patients with MIBG Positive Residual Metastatic Disease. Pediatr. Blood Cancer, 64. S. S33 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Tulla, M., Berthold, F., Graf, N., Rutkowski, S., von Schweinitz, D., Spix, C. and Kaatsch, P. (2015). Incidence, Trends, and Survival of Children With Embryonal Tumors. Pediatrics, 136 (3). S. E623 - 10. ELK GROVE VILLAGE: AMER ACAD PEDIATRICS. ISSN 1098-4275

Van Zogchel, L., De Carolis, B., van Wezel, E., Stutterheim, J., Zappeij-Kannegieter, L., van Doornum, M., Schumacher-Kuckelkorn, R., Gecht, J., Simon, T., Caron, H., Fiocco, M., van der Schoot, E., Hero, B., Berthold, F. and Tytgat, G. (2018). Detection of Minimal Residual Disease (MRD) in High Risk Neuroblastoma Correlates with Outcome: Final Results of International GPOH-DCOG Prospective Validation Study. Pediatr. Blood Cancer, 65. S. S38 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Volland, R., Simon, T., Berthold, F. and Hero, B. (2015). CONFIRMATION OF THE INRG SURVIVAL TREE ANALYSIS BY A DIFFERENTLY COMPOSED REPRESENTATIVE NATIONAL COHORT OF PATIENTS. Pediatr. Blood Cancer, 62. S. S226 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

van Wezel, E., Decarolis, B., Stutterheim, J., Zappeij-Kannegieter, L., Hero, B., Berthold, F., Simon, T., Schumacher-Kuckelkorn, R., van Noesel, M., Fiocco, M., Caron, H., van der Schoot, C. E. and Tytgat, G. (2015). MINIMAL BONE MARROW DISEASE IS FREQUENTLY DETECTED IN LOCALIZED NEUROBLASTOMA PATIENTS. Pediatr. Blood Cancer, 62. S. S226 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

This list was generated on Thu Mar 28 12:50:11 2024 CET.